Theseus Stock Analysis

THRX -  USA Stock  

USD 9.96  0.05  0.50%

The current slide in stock price created some momentum for investors as it was traded today as low as 9.45 and as high as 10.24 per share. The company directors and management have failed to build on market volatilities in December. However, diversifying your overall positions with Theseus Pharmaceuticals may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 9.93. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Theseus Pharmaceuticals partners.
Additionally, take a look at World Market Map.

Theseus Stock Analysis 

 
Refresh
The Theseus Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Theseus Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Theseus Stock analysis module also helps to analyze the Theseus Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Theseus Stock Analysis Notes

About 64.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 737.67. Theseus Pharmaceuticals recorded a loss per share of 22.92. The entity next dividend is scheduled to be issued on the September 8, 2015. The firm had 1241:1000 split on the June 3, 2014. Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Theseus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people. To find out more about Theseus Pharmaceuticals contact Michael Aguiar at 857-400-9491 or learn more at https://theseusrx.com.

Theseus Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Theseus Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Theseus Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Theseus Pharmaceuticals generated a negative expected return over the last 90 days
Theseus Pharmaceuticals has high historical volatility and very poor performance
Theseus Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 38.39 M. Net Loss for the year was (21.54 M) with profit before overhead, payroll, taxes, and interest of 8.43 M.
Theseus Pharmaceuticals currently holds about 90.4 M in cash with (18.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.39.
Roughly 64.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Theseus Pharmaceuticals exotic insider transaction detected

Theseus Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Theseus Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Theseus Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report17th of February 2016
Next Earnings Report4th of May 2016
Next Fiscal Quarter End31st of December 2015
Next Fiscal Year End17th of February 2016
Last Quarter Report30th of September 2015
Last Earning Announcement31st of December 2014

Theseus Largest EPS Surprises

Earnings surprises can significantly impact Theseus Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-10-07
2021-09-30-0.24-5.16-4.922050 
View All Earnings Estimates

Theseus Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 399.02 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Theseus Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Theseus Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of 1.82 % which means that it generated profit of $1.82 on every $100 spent on asset. This is way below average. Theseus Pharmaceuticals management efficiency ratios could be used to measure how well theseus pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 21st of January, Theseus Pharmaceuticals has the coefficient of variation of (3,488), and Risk Adjusted Performance of (0.014261). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Theseus Pharmaceuticals, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Theseus Pharmaceuticals, which can be compared to its competition. Please validate Theseus Pharmaceuticals semi deviation, jensen alpha, as well as the relationship between the Jensen Alpha and semi variance to decide if Theseus Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 9.96 per share. Given that Theseus Pharmaceuticals has jensen alpha of (0.28), we advise you to double-check Theseus Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.

Theseus Pharmaceuticals Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Theseus Pharmaceuticals price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average. View also all equity analysis or get more info about triple exponential moving average t3 overlap studies indicator.

Theseus Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Theseus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Theseus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Theseus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Theseus Pharmaceuticals Predictive Daily Indicators

Theseus Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Theseus Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Theseus Pharmaceuticals Forecast Models

Theseus Pharmaceuticals time-series forecasting models is one of many Theseus Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Theseus Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Theseus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Theseus Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Theseus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Theseus Pharmaceuticals. By using and applying Theseus Stock analysis, traders can create a robust methodology for identifying Theseus entry and exit points for their positions.
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Theseus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Theseus Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Backtesting Now

   

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Module
Additionally, take a look at World Market Map. Note that the Theseus Pharmaceuticals information on this page should be used as a complementary analysis to other Theseus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Theseus Stock analysis

When running Theseus Pharmaceuticals price analysis, check to measure Theseus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theseus Pharmaceuticals is operating at the current time. Most of Theseus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Theseus Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Theseus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Theseus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Is Theseus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theseus Pharmaceuticals. If investors know Theseus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theseus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Theseus Pharmaceuticals is measured differently than its book value, which is the value of Theseus that is recorded on the company's balance sheet. Investors also form their own opinion of Theseus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Theseus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theseus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Theseus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theseus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Theseus Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theseus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.